RE:CZO's science published in top 3% journal this week...CZO is six months into the second leg of the studies with the Angiogenesis Foundation which should set CZO up for a partnership deal:
“While Ceapro has so far evolved in dermatology by providing active ingredients serving the cosmetic sector, additional expected evidence-based results from this study will not only reinforce and/or add claims to existing cosmetics formulations but should further position Ceapro in dermatology along with a pharmaceutical and medical supplies partner who will benefit from additional selling points arising from this unique research program." news release